.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH04_Alogliptin.Alogliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH04_Alogliptin.Alogliptin| name: | Alogliptin |
| ATC code: | A10BH04 | route: | oral |
| n-compartments | 1 |
Alogliptin is an oral antihyperglycemic agent, classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, used in the management of type 2 diabetes mellitus to improve glycemic control. It is approved for adult use and is available as a prescription medication in several countries.
Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration.
Naik, H, et al., & Vakilynejad, M (2016). Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin. British journal of clinical pharmacology 81(4) 700–712. DOI:10.1111/bcp.12853 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26617339
Scheen, AJ (2015). Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clinical pharmacokinetics 54(1) 1–21. DOI:10.1007/s40262-014-0198-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25331711